NRE-1 In progress
OPHTHALMOLOGY ( HIGH YIELD ) VIDEO LECTURES
Enrolled October 2026
14 of 16 lectures 92%
Verified FAME student
SALMAN ALI KHAN
Xinxiang Medical University, Henan China, Xinxiang
NRE-1
- 18
- Courses Enrolled
- 13
- Mock Tests Attempted
- 81%
- Best Mock Score
Performance
Overall Progress
Mock score progress
Pass mark 70%
Question Bank Overall performance
44% correct
- Completed 357/576
- Correct 256
- Wrong 101
- Omitted 219
Average score by subject
Orange marks a subject below the 70% pass mark.
Enrolled Courses
Student Learning Journey
NRE-1 In progress
Bailey & Love Surgery
Enrolled September 2026
22 of 80 lectures 28%
NRE-1 In progress
6. PMDC/PMC Mock Test
Enrolled September 2026
13 of 97 lectures 13%
NRE-1 In progress
NRE MADE EASY 7th Edition LIVE SESSION
Enrolled September 2026
3 of 32 lectures 9%
NRE-1 In progress
WAHAB DOGAR GENERAL & SYSTEMIC SURGERY LECTURES
Enrolled September 2026
5 of 60 lectures 8%
USMLE STEP-1 In progress
First Aid Step-1 Video Lectures
Enrolled September 2026
27 of 522 lectures 5%
Attempted Mock Tests
- NRE-1 Gynecology and Obstetrics MOCK TEST Passed 75%
- NRE Mock test Gynae and Obs 2025 Not passed 55%
- NRE-1 CNS & PSYCHIATRY SYSTEM OCTOBER ATTEMPT CRASH COURSE MOCK TEST 2026 Not passed 2%
- NRE-1 Reproductive System Mock Test Not passed 58%
- NRE-1 Hematology for June attempt 2026 Not passed 0%
- NRE-1 Renal System June Mock Test 2026 Passed 74%
- NRE 1 Biochemistry Mock Test 16th November 2024 Not passed 41%
- NRE-1 SURGERY MOCK TEST MAY ATTEMPT Not passed 0%
- NRE-1 Paeds Mock test (Crash course Dec attempt 2025) Passed 81%
- NRE-1 Surgery June Mock Test 2026 Not passed 50%
- NRE-1 MAY ATTEMPT GRAND MOCK TEST Part-2 Passed 74%
- NRE-1 17 MAY GRAND MOCK TEST Part-1 Passed 74%
- NRE-1 EYE ENT June Mock Test 2026 Passed 76%
OPHTHALMOLOGY ( HIGH YIELD ) VIDEO LECTURES
LECTURE 7 (NOT WORKING) AND LECTURE 15 (VOICE DISTORTION)
SALMAN ALI KHAN Xinxiang Medical University, Henan China, Xinxiang
Preparing for NRE-1 too?
Browse courses
© 2026 First Aid Made Easy (FAME). All Rights Reserved.